InspireMD (NYSE:NSPR) Insider Shane Thomas Gleason Sells 9,923 Shares

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 9,923 shares of the stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $2.55, for a total value of $25,303.65. Following the completion of the sale, the insider owned 1,116,806 shares of the company’s stock, valued at approximately $2,847,855.30. This trade represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The shares were sold at an average price of $1.01, for a total value of $23,005.78.

InspireMD Stock Performance

InspireMD stock opened at $1.03 on Friday. The stock has a 50-day moving average of $1.39 and a two-hundred day moving average of $1.67. InspireMD, Inc. has a one year low of $0.97 and a one year high of $2.93. The stock has a market cap of $48.24 million, a PE ratio of -1.37 and a beta of 0.82.

Wall Street Analyst Weigh In

A number of research firms have commented on NSPR. Loop Capital set a $5.00 price target on InspireMD in a research note on Tuesday, February 24th. Maxim Group began coverage on InspireMD in a research note on Monday, February 2nd. They issued a “buy” rating and a $6.00 price target for the company. Piper Sandler reiterated an “overweight” rating and issued a $3.00 price target (down from $4.00) on shares of InspireMD in a research note on Tuesday, May 5th. Finally, Lake Street Capital set a $4.00 price target on InspireMD in a research note on Monday, May 4th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $4.50.

Institutional Trading of InspireMD

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC acquired a new stake in InspireMD during the first quarter worth about $29,000. Virtu Financial LLC acquired a new stake in InspireMD during the fourth quarter worth about $31,000. XTX Topco Ltd acquired a new stake in InspireMD during the fourth quarter worth about $30,000. Orbimed Advisors LLC grew its holdings in InspireMD by 46.9% during the fourth quarter. Orbimed Advisors LLC now owns 3,133,405 shares of the company’s stock worth $5,577,000 after acquiring an additional 1,000,000 shares during the period. Finally, Essex Investment Management Co. LLC acquired a new stake in InspireMD during the fourth quarter worth about $203,000. 44.78% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about InspireMD

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: There were no clearly positive company-specific announcements in the latest items, so investor attention is centered on the stock’s low valuation and recent trading near its 1-year low. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The most recent insider sale was small and attributed to tax withholding obligations tied to equity award vesting, which often makes the transactions less concerning than open-market selling. Multiple similar sales were also reported earlier this year. SEC filing
• Negative Sentiment: Repeated insider sales can still weigh on sentiment, as investors may view them as a sign of limited near-term upside or a lack of conviction from management, especially for a small-cap stock already trading below its recent moving averages. SEC filing

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.